Biofrontera (BFRI) Competitors

Daré Bioscience (NASDAQ:DARE) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings, valuation and community ranking.

Do insiders & institutionals believe in DARE or BFRI?

6.7% of Daré Bioscience shares are owned by institutional investors. Comparatively, 10.1% of Biofrontera shares are owned by institutional investors. 4.0% of Daré Bioscience shares are owned by company insiders. Comparatively, 0.2% of Biofrontera shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Do analysts rate DARE or BFRI?

Daré Bioscience currently has a consensus price target of $24.00, indicating a potential upside of 727.59%. Biofrontera has a consensus price target of $7.00, indicating a potential upside of 723.53%. Given Daré Bioscience's higher possible upside, research analysts clearly believe Daré Bioscience is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daré Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Biofrontera	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community favor DARE or BFRI?

Daré Bioscience received 350 more outperform votes than Biofrontera when rated by MarketBeat users. Likewise, 73.36% of users gave Daré Bioscience an outperform vote while only 66.67% of users gave Biofrontera an outperform vote.

Company	Underperform	Outperform
Daré Bioscience	Outperform Votes 358 73.36%	Underperform Votes 130 26.64%
Biofrontera	Outperform Votes 8 66.67%	Underperform Votes 4 33.33%

Is DARE or BFRI more profitable?

Biofrontera has a net margin of -36.31% compared to Daré Bioscience's net margin of -191.65%. Daré Bioscience's return on equity of 0.00% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Daré Bioscience	-191.65%	N/A	-18.98%
Biofrontera	-36.31%	-565.73%	-96.64%

Which has more volatility and risk, DARE or BFRI?

Daré Bioscience has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, Biofrontera has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500.

Does the media favor DARE or BFRI?

In the previous week, Daré Bioscience and Daré Bioscience both had 2 articles in the media. Biofrontera's average media sentiment score of 0.99 beat Daré Bioscience's score of 0.14 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Daré Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biofrontera	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger valuation and earnings, DARE or BFRI?

Biofrontera has higher revenue and earnings than Daré Bioscience. Daré Bioscience is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daré Bioscience	$9.78K	2,623.16	-$30.16M	-$0.51	-5.69
Biofrontera	$37.32M	0.20	-$20.13M	-$2.26	-0.38

Summary

Daré Bioscience beats Biofrontera on 10 of the 17 factors compared between the two stocks.